FDA Warns About Musculoskeletal Pain With Bisphosphonate Use
This article was originally published in The Pink Sheet Daily
Agency asks physicians to consider discontinuing treatment despite lack of causal link to pain.
You may also be interested in...
Recent journal articles on the osteoporosis products’ association with atrial fibrillation spark an “early safety communication" from the agency.
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.